Related Experiment Video

Updated: Aug 4, 2026

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

Lamotrigine monotherapy in children

T F Barron1, S L Hunt, T F Hoban

  • 1Section of Pediatric Neurology, Department of Pediatrics, M.S. Hershey Medical Center, Pennsylvania State University, College of Medicine;, Hershey, Pennsylvania, USA.

Pediatric Neurology
|October 6, 2000
PubMed

Insights

Lamotrigine effectively treats pediatric epilepsy, with 45% of children becoming seizure-free. This epilepsy medication shows promise as a first-line treatment option for both focal and generalized seizures in children.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy affects a significant number of children worldwide.
  • Monotherapy is often preferred for managing pediatric epilepsy to minimize polypharmacy.
  • Lamotrigine is an established antiepileptic drug with a known safety profile.

Purpose of the Study:

  • To retrospectively evaluate the effectiveness of lamotrigine as a monotherapeutic agent in pediatric epilepsy.
  • To assess treatment response in children with focal versus generalized epilepsy.
  • To determine the efficacy in both antiepileptic drug-naive and drug-exposed pediatric populations.

Main Methods:

  • Retrospective review of 83 pediatric patients with epilepsy treated with lamotrigine monotherapy.
  • Patients categorized by epilepsy type (focal vs. generalized) and prior drug exposure.
  • Data collected included dosages, side effects, follow-up duration, and seizure control (defined as seizure-free for ≥6 months).

Main Results:

  • Overall, 45% of pediatric patients achieved seizure freedom for 6 months or more.
  • Efficacy was observed in both focal epilepsy (44% seizure-free) and generalized epilepsy (36% seizure-free).
  • Rash was the most common side effect (6%), with no cases of Stevens-Johnson syndrome reported.

Conclusions:

  • Lamotrigine demonstrates effectiveness as a monotherapeutic agent for various pediatric epilepsies, including focal and generalized types.
  • The drug is generally well-tolerated, with a low incidence of significant side effects.
  • Lamotrigine may be a suitable and effective first-line treatment option for pediatric epilepsy.

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...